title: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
abstract: Predisposition to prostate cancer has a genetic component, and there are reports of familial clustering of breast and prostate cancer. Two highly penetrant genes that predispose individuals to breast cancer (BRCA1 and BRCA2) are known to confer an increased risk of prostate cancer of about 3-fold and 7-fold, respectively, in breast cancer families. Blood DNA from affected individuals in 38 prostate cancer clusters was analyzed for germ-line mutations in BRCA1 and BRCA2 to assess the contribution of each of these genes to familial prostate cancer. Seventeen DNA samples were each from an affected individual in families with three or more cases of prostate cancer at any age; 20 samples were from one of affected sibling pairs where one was < or = 67 years at diagnosis. No germ-line mutations were found in BRCA1. Two germ-line mutations in BRCA2 were found, and both were seen in individuals whose age at diagnosis was very young (< or = 56 years) and who were members of an affected sibling pair. One is a 4-bp deletion at base 6710 (exon 11) in a man who had prostate cancer at 54 years, and the other is a 2-bp deletion at base 5531 (exon 11) in a man who had prostate cancer at 56 years. In both cases, the wild-type allele was lost in the patient's prostate tumor at the BRCA2 locus. However, intriguingly, in neither case did the affected brother also carry the mutation. Germ-line mutations in BRCA2 may therefore account for about 5% of prostate cancer in familial clusters.
authors.affiliation: Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Addenbrook's Hospital, United Kingdom.
authors.forename: S A
authors.initials: SA
authors.lastname: Gayther
authors.forename: K A
authors.initials: KA
authors.lastname: de Foy
authors.forename: P
authors.initials: P
authors.lastname: Harrington
authors.forename: P
authors.initials: P
authors.lastname: Pharoah
authors.forename: W D
authors.initials: WD
authors.lastname: Dunsmuir
authors.forename: S M
authors.initials: SM
authors.lastname: Edwards
authors.forename: C
authors.initials: C
authors.lastname: Gillett
authors.forename: A
authors.initials: A
authors.lastname: Ardern-Jones
authors.forename: D P
authors.initials: DP
authors.lastname: Dearnaley
authors.forename: D F
authors.initials: DF
authors.lastname: Easton
authors.forename: D
authors.initials: D
authors.lastname: Ford
authors.forename: R J
authors.initials: RJ
authors.lastname: Shearer
authors.forename: R S
authors.initials: RS
authors.lastname: Kirby
authors.forename: A L
authors.initials: AL
authors.lastname: Dowe
authors.forename: J
authors.initials: J
authors.lastname: Kelly
authors.forename: M R
authors.initials: MR
authors.lastname: Stratton
authors.forename: B A
authors.initials: BA
authors.lastname: Ponder
authors.forename: D
authors.initials: D
authors.lastname: Barnes
authors.forename: R A
authors.initials: RA
authors.lastname: Eeles
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000235:genetics*; D016000:Cluster Analysis; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics; D005091:Exons / Q000235:genetics; D005192:Family Health; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D018095:Germ-Line Mutation / Q000235:genetics*; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D010375:Pedigree; D011471:Prostatic Neoplasms / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D014157:Transcription Factors